Yusuf Yazici, MD

Yusuf Yazici, MD


Yusuf Yazici, MD, is an Assistant Professor of Medicine at the New York University School of Medicine. Dr. Yazici is also the Director of the Seligman Center for Advanced Therapeutics at the NYU Hospital for Joint Diseases and Director of the Behcet’s Syndrome Evaluation, Treatment and Research Center at NYU Hospital for Joint Diseases.

Dr. Yazici earned his medical degree from Cerrahpasa Medical Faculty of Istanbul University in Istanbul, Turkey. He completed his internship and residency at Creighton University in Nebraska and his fellowship in rheumatology at the Hospital for Special Surgery of Weill Medical College of Cornell University.

His areas of interest are rheumatoid arthritis, early arthritis; patient reported outcomes, database and registry management and monitoring of arthritis patients in regard to clinical response and adverse events related to treatment and Behcet’s syndrome. He has published over 100 articles and presented at various national and international meetings over 100 times.

He divides his time between seeing patients and running the Seligman center, both industry and investigator initiated trials, in the areas of RA and Behcet’s syndrome.


  1. Yazici Y, Yazici H. Informed consent: time for more transparency. Arthritis Res Ther. 2010 Jun 3;12(3):121.
  2. Yazici Y. Treatment of rheumatoid arthritis: we are getting there. Lancet. 2009 ;374: 210 – 21
  3. Yazici Y, Yazici H. Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis. Clin Exp Rheumatol. 2008;26:449-52.
  4. Yazici Y, Adler NM, Yazici H. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called ‘efficacy and safety’ trials: a survey of power considerations. Rheumatology (Oxford). 2008; 47: 1054-7.
  5. Yazici Y, Yazici H. A survey of inclusion of the time element when reporting adverse effects in randomized controlled trials of cyclooxygenase-2 and tumor necrosis factor alpha inhibitors. Ann Rheum Dis. 2007; 66: 124-7.
  6. Yazici Y, Kautiainen H, Sokka T. Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data. J Rheumatol. 2007; 34: 311-5.


Bookmark and Share